載入...
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
BACKGROUND: Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter 2, reduced the risk of hospitalization for heart failure and cardiovascular death in type 2 diabetic patients in the EMPA‐REG OUTCOME trial. Recent trials evidenced several cardio-renal benefits of EMPA in n...
Na minha lista:
| 發表在: | Cardiovasc Diabetol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8305868/ https://ncbi.nlm.nih.gov/pubmed/34301253 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-021-01346-y |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|